A Critical Re-Evaluation of "Activation-Induced Cytidine Deaminase: The Missing Piece of Many Puzzles" by Carvalho et al., Cell 2025;188(24):6691-6695. doi:10.1016/j.cell.2025.10.031

1 A Critical Re-Evaluation of “Activationinduced cytidine deaminase: The missing piece of many puzzles” by Carvalho et al., Cell 2025;188(24):6691-6695. doi:10.1016/j.cell.2025.10.031 Ruihuang Wang, Qinglan Zhu, Ying Xu and Shu-Feng Zhou* College of Chemical Engineering, Huaqiao University, Xiamen 361021, China *Correspondence: [email protected] Abstract Activation-induced cytidine deaminase (AID) remains one of the most enigmatic molecules in modern immunology, occupying a paradoxical position as both the engine of antibody diversification and a potent source of genomic instability. In their 2025 Cell article, Carvalho, Fagarasan and Muramatsu attempt to synthesize decades of disparate findings into a unified conceptual framework that casts AID as the “missing piece” linking B cell plasticity, genomic remodeling and adaptive immune fitness. Although the review succeeds in highlighting the historical impact and biological breadth of AID research, many of its mechanistic claims, narrative transitions and graphical summaries rely on selective interpretation rather than comprehensive evaluation. This commentary critically examines the review from molecular, cellular, genomic, translational and evolutionary dimensions, emphasizing inconsistencies between cited evidence and proposed mechanisms, oversimplifications of germinal center dynamics, and the omission of important negative regulatory pathways that shape AID function. A figure-by-figure critique reveals additional conceptual oversights, including ambiguities in pathway directionality, failure to represent structural constraints, and schematic representations that obscure causal uncertainties. Extended Data and Supplementary Figures further propagate unresolved contradictions in AID targeting, DNA repair choice, and mutational hierarchy. Important emerging domains such as single-cell multi-omics, chromatin topology, replication timing and RNA–protein interaction dynamics are either underdeveloped or absent, limiting the review’s integrative scope. By synthesizing alternative models, highlighting neglected evidence and proposing a corrected conceptual framework, this commentary aims to refine the mechanistic understanding of AID and strengthen 2 the theoretical foundations needed for future immunological, pathological and therapeutic advances. 3 1. Introduction 1.1. Historical Overview of AID Function in Immunology AID has occupied a central position in molecular immunology since its discovery as the factor responsible for initiating somatic hypermutation and class-switch recombination, two essential mechanisms that enable the adaptive immune system to generate high-affinity and functionally diverse antibodies1,2. Initially identified in the early 2000s as a B-cell–specific enzyme expressed during germinal center reactions, AID was rapidly recognized as the key initiator of programmed mutagenesis3-6. By deaminating cytidines in single-stranded DNA, AID creates uracil lesions that are subsequently processed by a combination of base excision repair, mismatch repair and error-prone polymerases, ultimately resulting in targeted sequence diversification at immunoglobulin loci1,4,7-9. This discovery revolutionized the conceptual understanding of antibody maturation by revealing that genomeediting processes underlie immune adaptation. Over the past decades, subsequent studies expanded AID’s role beyond a simple mutator to a multifaceted molecule involved in chromatin remodeling, DNA repair pathway selection and transcriptioncoupled genome dynamics5,6,9,10. Its evolutionary conservation among vertebrates underscored the enzyme’s fundamental role in balancing effective immune defense with genomic risk, a duality that remains at the heart of modern AID research. 1.2. Impact of AID on Somatic Hypermutation, Class-Switch Recombination and Genomic Instability The functional influence of AID extends beyond generating point mutations in immunoglobulin genes. Somatic hypermutation shapes the antigen-binding repertoire by creating extensive sequence diversity, while class-switch recombination reorganizes the antibody heavy-chain locus to produce distinct effector isotypes1,10. In both processes, AID activity is tightly linked to transcriptional activation and chromatin accessibility, operating at genomic sites where single-stranded DNA becomes exposed. However, despite the overall precision of these events, AID poses substantial risks. Its catalytic mechanism is inherently promiscuous, with the potential to target off-locus genomic regions, particularly highly transcribed genes. This off-target activity is implicated in chromosomal translocations, oncogene activation and lymphomagenesis. B cell malignancies such as diffuse large B cell lymphoma and Burkitt lymphoma exhibit mutational scars consistent with aberrant AID activity3,5, reflecting the vulnerability of germinal center B cells to mutational burden. The duality of AID therefore represents a biologically necessary compromise, enabling high-affinity humoral immunity at the cost of persistent mutational risk. The 2025 Cell review seeks to 4 elevate this duality into a conceptual scaffold for interpreting AID as a genomemodifying factor, yet its treatment of these mechanisms often simplifies or overextends the available evidence. 1.3. Why the 2025 Cell Review Attempts to Redefine the AID Landscape The review by Carvalho, Fagarasan and Muramatsu11 positions AID as the “missing piece” required to connect immunological, genomic and evolutionary perspectives. Their intent is to transcend earlier views that framed AID narrowly as a mutator enzyme and instead argue that AID functions as a broader orchestrator of genome plasticity, influencing transcriptional programs and possibly contributing to epigenetic regulation. This conceptual shift parallels a broader trend in immunology that emphasizes the deep integration of DNA damage responses with cellular differentiation and lineage commitment, particularly in germinal centers where B cells undergo rapid metabolic and transcriptional transitions. By attempting to consolidate these findings, the authors aim to unify disparate mechanistic studies under a single interpretive model. However, such unification carries risks. It may obscure unresolved controversies, magnify speculative connections or downplay the specificity of experimental evidence. The review’s framing also revisits longstanding debates about whether AID directly modulates epigenetic states, whether off-target lesions serve regulatory rather than accidental functions and whether AID participates in extrafollicular or innate immune pathways. These questions remain contentious and require careful, evidence-anchored analysis. 1.4. Aim and Scope of This Critical Commentary The purpose of this commentary is to provide a comprehensive and rigorous evaluation of the 2025 Cell review, examining its conceptual structure, evidentiary foundations and interpretational coherence. Unlike the review’s broad narrative approach, this commentary adopts a multi-dimensional analytic framework that dissects molecular, cellular, genomic, evolutionary and translational claims in parallel. Particular emphasis is placed on identifying logical gaps, unsupported generalizations and inconsistencies between the review’s assertions and the current empirical landscape. A detailed figure-by-figure critique is undertaken to evaluate the accuracy and transparency of the visual models that shape readers’ understanding of AID biology. Extended Data and Supplementary Figures are analyzed with equal scrutiny, as these materials frequently convey mechanistic implications not explicitly addressed in the main text. Furthermore, this commentary highlights emerging data from single-cell genomics, structural biology, replication timing studies and spatial immunology that contradict or complicate the 5 review’s conclusions. By systematically synthesizing these insights, the goal is to refine current models of AID function, expose conceptual weaknesses in the reviewed article and chart more accurate directions for future research. 2. Conceptual Framework of the Carvalho– Fagarasan–Muramatsu Review 2.1. Summary of the Authors’ Stated Hypothesis In their 2025 Cell article, Carvalho, Fagarasan and Muramatsu11 present AID as a unifying molecular nexus that integrates antibody diversification, genome plasticity and adaptive immune evolution. Their central hypothesis argues that AID serves not merely as a mutagenic enzyme confined to immunoglobulin loci but as a broadly acting genomic modulator whose activity orchestrates transcriptional responsiveness, chromatin restructuring and B cell fate transitions. In this framework, AID is portrayed as a strategic evolutionary innovation that equips vertebrates with the capacity to reshape their immunogenetic architecture in response to antigenic challenges. The authors emphasize that AID’s mutational output is both mechanistically controlled and biologically purposeful, proposing that off-target lesions and DNA repair intermediates may contribute to physiological processes beyond classical antigen selection. This hypothesis fundamentally expands the scope of AID from its well-characterized canonical roles to a more speculative set of genome-wide regulatory functions. While ambitious and intellectually appealing, the hypothesis relies on conceptual connections that are often weakly anchored in direct experimental evidence, resulting in a narrative that blends established principles with conjecture. 2.2. Placement of AID within Systemic Immunobiology The review situates AID within a broader systems-level architecture of immune regulation, asserting that AID-mediated DNA lesions form signaling hubs that influence B cell survival, differentiation and metabolic tuning11. AID is positioned as a master integrator of cues from T follicular helper cells, germinal center microanatomy and inflammatory cytokines, with the authors suggesting that DNA damage responses triggered by AID serve as checkpoints to calibrate B cell plasticity. This systemic framing attempts to reconcile diverse fields—genome instability, somatic evolution, metabolic adaptation and transcriptional remodeling—into a single coordinated model. Yet this placement depends on viewing AID not only as a mutator but as a molecular interpreter of environmental signals. The review does not adequately address the difficulty of distinguishing direct AID-dependent regulatory functions from secondary consequences of DNA 6 repair and cellular stress. Furthermore, the systemic model underplays the contribution of context-dependent variables, such as germinal center zoning, cell cycle state and chromatin constraints, which significantly influence AID targeting and mutational outcomes. Consequently, the systemic interpretation risks overstating the coherence of AID’s influence across biological levels. 2.3. Conceptual Tensions between DNA Damage, Epigenetics and Antibody Diversification A central conceptual tension in the review lies in its attempt to unify disparate mechanistic layers—DNA damage induction, epigenetic modification and evolutionary antibody optimization—into a single continuum of AID-driven genome remodeling11. The authors imply that uracil lesions generated by AID not only fuel somatic hypermutation but also interface with epigenetic pathways, potentially influencing chromatin accessibility or transcriptional responsiveness. However, the evidence supporting a direct role of AID in epigenetic regulation is inconsistent. Early suggestions that AID participates in demethylation pathways have been challenged by more recent biochemical and genetic studies demonstrating that AID’s enzymatic activity remains tightly restricted to cytidine deamination and that changes in DNA methylation patterns can often be attributed to secondary effects of DNA repair processes rather than intrinsic AID targeting. In conflating these processes, the review risks obscuring mechanistic specificity and attributing regulatory significance to what may be incidental or compensatory responses. The authors also posit that AID creates a mutational landscape that acts as an evolutionary substrate for antibody diversification, yet the review does not fully address the relative contributions of DNA repair, selection, clonal competition and microenvironmental constraints. These conceptual tensions undermine the cohesiveness of the proposed unified model. 2.4. Overarching Narrative Inconsistencies Although the review aspires to reframe AID as a broad regulator of immunogenomic architecture, the narrative contains several inconsistencies that weaken its interpretational clarity. At times, AID is depicted as an enzyme with highly constrained specificity, targeting immunoglobulin loci with exquisite precision. In other passages, it is characterized as a genome-wide mutator whose activities extend far beyond the B cell receptor locus. These two depictions are difficult to reconcile without a detailed mechanistic account of how AID balances precision and promiscuity, an explanation the review does not provide. Similarly, AID is alternately described as a driver of regulated mutagenesis and as a passive participant in global DNA repair pathways, creating ambiguity about whether the 7 enzyme acts upstream or downstream of chromatin and transcriptional changes. The review also inconsistently frames AID’s off-target effects, sometimes treating them as physiologically meaningful sources of adaptive plasticity and elsewhere attributing them to unavoidable collateral damage. Such narrative oscillations suggest an underlying uncertainty regarding the conceptual boundaries of AID function. Without a cohesive mechanistic framework, the overarching message becomes diffuse and difficult to operationalize. 2.5. Missing Mechanistic Links A critical weakness in the review’s conceptual architecture is the absence of mechanistic links that would substantiate the extended roles attributed to AID. The proposed connections between AID activity and transcriptional reprogramming, chromatin remodeling or metabolic transitions lack the molecular intermediates necessary to support causal coherence. For example, the review does not address how AID-generated uracils might directly modulate histone marks, transcription factor recruitment or three-dimensional genome architecture. It also overlooks key regulators such as Spt5, replication protein A and DNA repair scaffolds that define the biochemical context in which AID operates. Likewise, the model does not integrate the substantial evidence that AID targeting requires specific transcriptional configurations, such as convergent transcription or enhancer– promoter looping, which restrict the locations and consequences of AID-mediated lesions. By omitting these mechanistic details, the review leaves its broader claims suspended without the molecular scaffolding required for plausibility. This absence of mechanistic bridges not only weakens the authors’ overarching hypothesis but also obscures the complexity of the regulatory networks that constrain AID activity. 3. Evidence Base and Literature Integration 3.1. Breadth of Literature Cited and Major Omissions The 2025 Cell review seeks to synthesize two decades of research on AID, yet the breadth of literature cited is uneven, leading to a conceptual imbalance that affects the strength of the review’s arguments. Foundational studies on somatic hypermutation, class-switch recombination and AID biochemistry are covered, but key developments from the past five years—particularly those involving single-cell multi-omics, replication timing, high-resolution chromatin topology and structural analyses of AID complexes—are underrepresented or absent. This selective citation pattern narrows the review’s interpretive bandwidth. For example, recent evidence demonstrating that AID targeting is modulated by enhancer–promoter interactions and transcriptional pausing is scarcely acknowledged, even though such studies fundamentally reshape the understanding of AID specificity. Additionally, literature 8 on negative regulators of AID, including those that modulate nuclear import, degradation and RNA-binding interactions, is inconsistently integrated, resulting in an inflated portrayal of AID as an autonomous regulatory engine rather than a tightly constrained enzymatic factor. Omissions of studies on off-target mutagenesis in non-lymphoid tissues and on the relationship between AID activity and B cell metabolic transitions further compromise the review’s comprehensiveness. These gaps create an interpretive asymmetry in which evidence that supports the authors’ speculative framework is highlighted, while evidence that introduces mechanistic limitations or alternative explanations is minimized or excluded. 3.2. Misalignment between Cited Evidence and Conceptual Claims Beyond selective citation, the review exhibits frequent misalignment between the evidence cited and the claims advanced. Several citations are used to imply direct causal links between AID activity and broader epigenetic remodeling, despite those studies offering only correlative data or proposing speculative models. For example, references discussing AID’s potential role in demethylation are invoked as support for a generalized epigenetic function, even though more rigorous biochemical work has shown that AID lacks intrinsic deamination activity on 5-methylcytosine in physiological contexts. This misalignment creates logical inflation, where limited or ambiguous findings are extrapolated into broad mechanistic statements. Similarly, studies documenting off-target AID-induced breaks are deployed to suggest their functional integration into gene regulatory programs, but no experimental evidence supports the idea that such lesions are physiologically adaptive rather than stochastic and repair-dependent. Equally problematic is the partial or decontextualized use of literature on chromosomal translocations. Several cited studies demonstrate off-target AID activity in genomic regions susceptible to oncogenic rearrangements; however, the review reframes these outcomes as potentially regulated processes, despite a lack of evidence for selective or beneficial off-target break induction. These interpretational misalignments undermine the credibility of the review’s broader conceptual claims by overstating the functional significance of speculative associations. 3.3. Discussion of Contradictory Findings in AID Regulation While the authors emphasize that AID is controlled through multiple layers of transcriptional, post-transcriptional and post-translational regulation, they do not adequately address contradictory findings in the literature that challenge the universality of these regulatory mechanisms. Reports indicating that AID nuclear localization is stochastic and only partially dependent on described import 9 pathways are not reconciled with the review’s portrayal of a highly orchestrated regulatory system. Similarly, studies demonstrating that AID can function outside germinal centers, particularly in extrafollicular B cell activation or chronic inflammatory responses, are inconsistently integrated. Some findings suggest that AID expression in non-canonical contexts may be regulated by stress-related transcription factors rather than germinal center-specific cues, yet the review conflates these distinct regulatory regimes into a monolithic model. Contradictions also exist in the literature regarding AID’s off-target profile, with some studies reporting broad genome-wide activity while others find strict locus-specific targeting dependent on chromatin accessibility and transcriptional architecture. The review does not critically engage with these discrepancies, nor does it provide a framework for reconciling conflicting observations. By overlooking these contradictions, the authors present a simplified narrative that masks the complexity of AID regulatory dynamics and weakens their interpretive model. 3.4. Limits of Correlative Evidence Presented Much of the evidence leveraged in the review is correlational, yet the narrative frequently treats these correlations as if they establish causality. Observations that AID expression coincides with transcriptional remodeling or chromatin reconfiguration during germinal center reactions are interpreted as evidence that AID actively drives these changes, despite the absence of mechanistic intermediates. Similarly, associations between AID activity and emergent B cell phenotypes are portrayed as indicative of direct regulatory influence, even though these phenotypes may result from downstream selection pressures or DNA damage responses rather than AID itself. The review also draws connections between AID-induced uracil abundance and epigenetic transitions without demonstrating whether uracil processing events produce specific chromatin outcomes. Furthermore, the review employs evolutionary correlations, such as conservation of AID family proteins across species, to imply functional links that have not been experimentally validated. The reliance on correlational data becomes especially problematic when extrapolated into broad claims about genome-wide AID roles that remain unsupported by direct experimental evidence. This overinterpretation inflates the conceptual reach of AID and risks obscuring the distinction between plausible hypotheses and empirically grounded mechanisms. 3.5. New Data That the Review Should Have Incorporated In a rapidly evolving field, the omission of significant new datasets from the review diminishes its capacity to meaningfully redefine the AID landscape. Recent singlecell and spatial transcriptomics studies have illuminated the heterogeneity of AID expression within germinal centers, revealing that AID-high states are tightly linked 16 systems sometimes suppress AID-induced damage rather than promote diversification. The mechanistic omissions create an impression that AID breaks are inherently functional rather than contextually regulated, a position that is not supported by empirical data. 6.2. Questioning the Causality of AID-Driven Chromosomal Translocations Chromosomal translocations represent one of the most consequential off-target outcomes of AID activity, with many B cell malignancies bearing characteristic rearrangements such as IgH–MYC fusions5,6. The review acknowledges the oncogenic risks associated with AID but reframes certain translocations as potential byproducts of an evolutionary strategy that balances adaptive evolution with genomic fragility. This reframing, however, is speculative and unsupported by mechanistic evidence. Most translocations involving AID occur due to inadvertent collisions between transcription and repair machinery or due to aberrant resection of DSB ends, not through regulated processes. The review fails to distinguish between physiological DSBs at switch regions and pathogenic DSBs arising at offtarget sites, treating the two as if they share the same underlying logic. Furthermore, new genomic datasets reveal that many translocations emerge from replication timing asymmetries rather than from AID’s deaminase activity directly, a concept omitted entirely from the review. By overstating the functional meaningfulness of AID-driven translocations, the review risks normalizing genomic instability as an adaptive feature rather than acknowledging its largely accidental and deleterious nature. 6.3. The Missing Role of Replication Timing Recent studies have highlighted replication timing as a decisive factor in shaping AID-induced mutagenesis. Regions that replicate late in S phase, possess high transcriptional output or exhibit R-loop formation are disproportionately vulnerable to AID-mediated lesions. The review, however, does not incorporate replication timing into its conceptual analysis, leaving a significant mechanistic gap in its model of genome instability. Replication stress not only increases the likelihood of single-stranded DNA exposure but also modulates the recruitment of repair complexes, thereby influencing whether AID lesions result in point mutations, DSBs or catastrophic genomic outcomes. Omitting replication timing also prevents the review from integrating findings that off-target AID activity correlates with fragile genomic domains such as common fragile sites. Moreover, the interplay between replication origins, chromatin loop architecture and transcriptional elongation rates all influence AID accessibility, yet these topics are absent from the 17 review’s discussion. Without acknowledging replication timing, the review’s narrative about AID’s genome-wide influence remains incomplete and mechanistically insufficient. 6.4. Discrepancies in the Proposed Mutational Hierarchy The review proposes a hierarchy of mutational consequences driven by AID, ranging from point mutations at immunoglobulin loci to more complex genomic rearrangements at off-target sites. However, this hierarchy is presented as if regulated by intrinsic AID preferences rather than the outcome of differential lesion processing and DNA repair pathway choices. Experimental evidence demonstrates that the mutational hierarchy arises not from differences in AID’s catalytic behavior but from the biochemical context in which lesions occur. For instance, clustered AID lesions can overload repair pathways and generate double-strand breaks, whereas sparse lesions may be resolved through error-free repair. The review minimizes the importance of lesion density, chromatin mobility and spatial genome organization in shaping this hierarchy, instead attributing outcomes to speculative AID-driven regulatory functions. Furthermore, the review overlooks evidence that the hierarchy is influenced by transcriptional strength, R-loop dynamics and replication-transcription conflicts. These discrepancies weaken the argument that the hierarchy reflects a coherent regulatory strategy rather than emergent properties of DNA damage and repair systems interacting under stress. 6.5. Failure to Integrate Cancer Genomics Despite acknowledging that AID contributes to oncogenic mutations, the review fails to adequately integrate insights from cancer genomics, which offer some of the strongest evidence for AID’s deleterious potential. Sequencing studies across B cell malignancies consistently reveal AID-associated mutational signatures that extend far beyond immunoglobulin loci, including kataegis clusters, aberrant hypermutation patterns and long-range translocation events. These datasets highlight the extent to which AID activity can destabilize the genome when regulatory constraints falter. Yet the review downplays the magnitude and complexity of such mutational landscapes, instead implying that off-target events may represent regulated or adaptive processes. Cancer genomic analyses contradict this interpretation by demonstrating that AID’s mutational imprint correlates strongly with genomic fragility, replication timing and stochastic DNA damage rather than with orchestrated regulatory control. Moreover, the review does not address findings that AID expression outside the germinal center—whether through chronic inflammation, viral infection or aberrant signaling—can induce widespread genome instability. Without incorporating these cancer genomics perspectives, the review presents an unrealistically sanitized portrayal of AID’s mutagenic capacity, 18 failing to acknowledge that the same mechanisms enabling antibody diversification also pose profound oncogenic risks. 7. AID beyond Classical Immunology 7.1. AID in Mucosal Immunity The review briefly touches on AID’s relevance to mucosal immunity but does not fully contextualize the enzyme’s activity within the unique architectural and microbial pressures of mucosal environments. Peyer’s patches and isolated lymphoid follicles are primary sites of IgA class-switch recombination, and AID expression in these tissues is shaped by antigen uptake, microbial metabolites and epithelial–immune interactions. Yet the review portrays mucosal AID activity as merely an extension of systemic germinal center processes, overlooking the specialized regulatory features that distinguish mucosal immune responses. For example, T-independent class switching, a hallmark of mucosal immunity, occurs under different signaling conditions than T-dependent germinal center reactions, yet the authors do not differentiate between these processes. AID expression in mucosal tissues is also influenced by retinoic acid, TGF-β and microbiota-derived short-chain fatty acids, none of which are incorporated into the review’s conceptual model. By neglecting these context-specific regulatory cues, the review misrepresents mucosal AID activity as if it follows the same mechanistic framework observed in systemic lymphoid organs. Furthermore, the review does not acknowledge evidence that chronic mucosal inflammation can drive aberrant AID expression, contributing to genomic instability in epithelial cells, a phenomenon with implications for inflammatory bowel disease and colorectal carcinogenesis. This omission underscores a broader issue: the review’s inability to address tissuespecific diversifications of AID function. 7.2. AID in Inflammation and Chronic Infection AID expression is not confined to homeostatic germinal center responses; inflammatory cytokines can induce ectopic or prolonged AID expression, creating mutagenic environments that deviate from classical immune activation. The review hints at inflammation-induced AID activity but does not assess the full scope of its mechanistic and pathological relevance. Chronic infections, such as those caused by Helicobacter pylori or hepatitis C virus, have been shown to induce AID expression in epithelial and hepatic tissues, respectively. These phenomena suggest that AID can be aberrantly activated outside B cells, contributing to carcinogenesis through off-target DNA deamination. Yet the review does not integrate these findings into its conceptual framework, missing an opportunity to examine how inflammationdriven AID expression challenges the notion that the enzyme’s mutagenic activity is 19 predominantly beneficial or immunologically constrained. Even within B cells, chronic infection alters AID regulation by disrupting germinal center architecture, prolonging exposure to DNA-damaging signals and skewing repair pathway usage. These deviations produce mutational patterns distinct from those observed during acute immune responses, but the review does not consider how chronic inflammation shapes AID’s activity or consequences. Without addressing these dimensions, the review presents an overly sanitized depiction of AID, ignoring the enzyme’s documented roles in pathogenic processes. 7.3. AID in Innate Immune Crosstalk The review briefly speculates about potential interactions between AID and innate immunity but does not substantiate these speculations with mechanistic insights. Recent research has revealed that innate immune sensors, including Toll-like receptors and cytosolic nucleic acid sensors, can influence AID expression by modulating transcription factors such as NF-κB and IRF family members. These pathways allow innate immune stimuli to shape B cell differentiation and mutational responses, yet the review treats AID as if it operates independently of innate inputs. Evidence also suggests that AID-induced DNA lesions can activate innate immune pathways, including cGAS–STING signaling, thereby linking genome instability to inflammatory responses. The review omits this bidirectional relationship, which is critical for understanding how AID-generated DNA damage can propagate immune signaling cascades. Moreover, innate-like B cell subsets, such as marginal zone and B-1 cells, exhibit distinct AID regulatory regimes that differ from those of follicular B cells. These subsets respond rapidly to innate stimuli and can undergo class switching in extrafollicular contexts, but the review does not acknowledge these mechanistic divergences. By downplaying innate–adaptive crosstalk, the review isolates AID within an artificially narrow adaptive framework and overlooks systems-level regulatory circuits. 7.4. Cross-Species Conservation and Misinterpretations The review invokes evolutionary conservation to argue for broad, integrated functions of AID, yet its treatment of comparative immunology lacks nuance. AID orthologs across vertebrates exhibit diverse functional capacities; some species rely on AID primarily for canonical immunoglobulin diversification, whereas others demonstrate alternative uses for cytidine deaminases in genome editing or antiviral responses. However, the review extrapolates from limited comparative evidence to propose that AID’s regulatory roles are evolutionarily conserved, a claim inconsistent with species-specific divergence in genomic architecture, immune system organization and mutation-handling strategies. Teleost fish, for example, possess AID but lack germinal centers, indicating that the enzyme’s canonical 20 functions can operate independently of the structural microenvironment that defines mammalian B cell selection. Such discrepancies challenge the review’s narrative that AID acts as a universal regulator of immune evolution. Furthermore, recent phylogenetic analyses suggest that AID diversification correlates with species-specific expansions of repair pathways rather than with conserved regulatory roles. The review overlooks these complexities and instead uses evolutionary conservation as a rhetorical device to support speculative functional claims without adequately engaging with empirical variability. 7.5. Proposed but Unsupported Extra-Germinal Roles One of the most expansive and speculative aspects of the review concerns proposed AID functions outside germinal centers, including roles in transcriptional tuning, epigenetic remodeling, metabolic regulation and extrafollicular B cell activation. While it is true that AID expression can occur under certain non-GC conditions, the review overgeneralizes isolated observations into sweeping functional assertions. The idea that AID participates in global transcriptional reprogramming lacks mechanistic intermediates and contradicts evidence indicating that AID’s known substrates are restricted to ssDNA. Claims that AID influences epigenetic landscapes through direct demethylation have been largely refuted, yet the review reintroduces these hypotheses without acknowledging current biochemical consensus. The suggestion that AID affects metabolic transitions in B cells is similarly speculative and not supported by direct data. Extrafollicular antibody responses do involve AID, but the regulatory logic differs from that of germinal centers, and AID functions mainly in class switching rather than hypermutation. Without mechanistic grounding or supporting data, these proposed extra-germinal roles inflate AID’s conceptual reach while obscuring the enzyme’s well-defined biochemical constraints. 8. Figure-By-Figure Critical Analysis of Main Figures 8.1. Critical Analysis of Figure 1 Figure 1 in the review is designed to serve as the conceptual entry point to the authors’ argument that AID functions as the linchpin connecting antibody diversification, genome remodeling and adaptive evolution. The schematic portrays AID at the center of multiple converging pathways, depicted as if the enzyme directly interfaces with transcriptional machinery, epigenetic regulators, DNA repair complexes and cell-fate determinants. While visually appealing, the figure oversimplifies the mechanistic landscape by implying direct causal interactions that are either unproven or contradicted by empirical evidence. For example, the direct arrows linking AID to chromatin modifiers suggest that AID plays an instructive role 21 in epigenetic state transitions, a claim inconsistent with biochemical studies showing that AID lacks catalytic activity toward methylated substrates and does not interact stably with chromatin-remodeling complexes. The figure further implies a bidirectional regulatory relationship between AID and transcriptional pausing factors, when in reality AID depends on paused transcription for ssDNA exposure rather than influencing pausing itself. Another conceptual issue lies in the portrayal of AID as a genome-wide sensor or interpreter of environmental cues. The figure positions AID upstream of B cell fate decisions, giving the impression that mutational output directly regulates differentiation into plasma, memory or recycling GC B cells. This inversion of regulatory logic ignores the well-established dominance of transcription factors such as BCL6, IRF4 and MYC in governing fate outcomes, with AID contributing mutational diversity but not instructive control. Furthermore, Figure 1 employs a circular systems-biology diagram that implies homeostatic equilibrium, yet AID’s mutagenic activity is inherently destabilizing and tightly constrained. By representing AID as a stabilizing integrator rather than a controlled risk factor, the figure misleads readers regarding the biological asymmetry between beneficial and deleterious AID effects. In sum, Figure 1 functions more as a conceptual advertisement than an accurate mechanistic model, and its schematic liberties undermine the review’s credibility. 8.2. Critical Analysis of Figure 2 Figure 2 attempts to depict the molecular steps of somatic hypermutation and class-switch recombination, but the execution obscures mechanistic distinctions and introduces interpretive ambiguities. The figure shows AID engaging directly with immunoglobulin loci, generating uracils that are subsequently processed through multiple repair pathways. However, the representation conflates base excision repair, mismatch repair and error-prone polymerase recruitment as if these events occur concurrently or in a coordinated fashion. Experimental data show that these pathways compete, not collaborate, and the outcome depends heavily on local lesion density, DNA accessibility and cell-cycle stage. By depicting these pathways as parallel, the figure eliminates the critical mechanistic tensions that determine mutational outcomes. A second problem is the figure’s omission of nuclear import/export dynamics. AID’s nuclear fraction is extremely small due to continuous CRM-1–mediated export and rapid degradation, yet the figure presents AID as a stable nuclear resident capable of sustained interactions with target loci. This misrepresentation inflates AID’s mutational capacity and supports the review’s broader—but inaccurate—narrative that AID exerts widespread regulatory influence. 22 The figure also neglects to distinguish between the structured architecture of switch regions and the mutational hotspots within V genes. Instead, it represents both as generic DNA substrates, concealing the fact that transcriptional architecture, R-loop formation and enhancer-promoter looping differentiate these regions in ways critically relevant for AID targeting. Without acknowledging these distinctions, the figure inadvertently supports the speculative notion that AID possesses broad genomic reach, blurring important structural constraints. Finally, the figure mischaracterizes chromosomal translocations by depicting them as downstream extensions of physiological CSR. This narrative framing implies that translocations arise through regulated pathways rather than through accidents of repair failure, an interpretation lacking mechanistic justification. As such, Figure 2 oversimplifies complex molecular choreography and amplifies the authors’ speculative interpretations. 8.3. Critical Analysis of Figure 3 Figure 3 aims to present a model in which AID activity integrates with cellular metabolism, DNA damage responses and selection pressures to produce emergent germinal center behaviors. The figure is densely layered, giving an impression of mechanistic completeness, but it suffers from conceptual inflation and inaccurate depictions of regulatory hierarchy. For example, the placement of AID at the convergence point of metabolic signals implies that glycolytic and oxidative shifts directly regulate AID’s catalytic function. While metabolic state affects proliferation, redox balance and transcriptional tempo, there is no evidence demonstrating direct metabolic modulation of AID enzymatic activity. By suggesting such a connection, the figure extrapolates beyond empirical support and risks misleading readers into accepting speculative cross-talk as established fact. The depiction of DNA damage checkpoints in Figure 3 also lacks nuance. The figure shows AID-generated lesions activating checkpoint kinases in a controlled manner, diagrammed as arrows feeding into cell-fate decision nodes. In reality, AID-induced DNA lesions activate heterogeneous and sometimes stochastic damage-response pathways that often act to suppress mutagenesis rather than integrate it into developmental programming. The figure falsely implies that DNA damage is a tuned regulatory input rather than a risk that must be mitigated through tightly regulated mechanisms. Additionally, the figure overextends the interpretation of spatial germinal center biology. AID-high cells are shown localized to discrete metabolic niches, implying that AID expression defines spatial dynamics. However, imaging studies demonstrate that spatial distribution reflects chemokine gradients, antigen presentation and cell density constraints, factors largely independent of AID 23 expression levels. By representing AID as shaping germinal center architecture rather than responding to it, the figure reverses established causal relationships. Finally, the graphical layering style used in Figure 3—overlapping feedback loops, bidirectional arrows and stacked signaling modules—creates false symmetry among pathways with vastly different mechanistic certainty. Established transcriptional regulators appear alongside speculative AID-centric hypotheses, giving the latter unwarranted parity. As a result, the figure obscures rather than clarifies the mechanistic heterogeneity underlying germinal center function. 8.4. Critical Analysis of Figure 4 Figure 4 attempts to synthesize the review’s central thesis by presenting AID as a genome-wide architectural modulator, positioned within a landscape of transcriptional units, enhancer networks and chromosomal territories. This figure represents the most speculative aspect of the review and illustrates many of its conceptual weaknesses. The graphical depiction of AID interacting with 3D chromatin loops suggests that AID plays an active role in shaping loop dynamics or enhancer-promoter communication. However, all available structural and biochemical evidence indicates that AID has no recognized capability to induce or stabilize higher-order chromatin architecture. AID binds transiently to ssDNA and relies entirely on transcriptional byproducts for target exposure. The figure’s depiction of AID as a chromatin sculptor therefore lacks mechanistic grounding and conveys an inflated understanding of AID’s physicochemical capacities. The representation of transcriptional hubs containing AID is similarly misleading. By showing AID colocalized with general transcription factors and cohesin complexes, the figure suggests direct regulatory interactions. Yet co-localization in schematic form does not reflect biological co-complex formation, and experimental evidence shows no stable interactions that would position AID as a component of transcriptional machinery. Moreover, the figure depicts AID as influencing replication fork progression, a concept with no biochemical basis and contradicted by studies demonstrating that AID-induced lesions are generally incompatible with ongoing replication and instead provoke replication stress. Furthermore, the figure attempts to portray AID as an orchestrator of genome-wide epigenetic remodeling by linking AID dots to methylated regions and histonemodifying complexes. This visual narrative reintroduces outdated models of AIDmediated demethylation, ignoring recent biochemical refutations. The figure’s messaging therefore conflicts with contemporary scientific consensus, perpetuating misconceptions that undermine mechanistic clarity. 24 8.5. Critical Analysis of the Graphical Summary Model The final graphical summary consolidates the review’s broadest claims, depicting AID as the missing integrative element that harmonizes somatic evolution, genomic plasticity and adaptive immunity. This model is presented as a unifying conceptual scaffold, yet its visual structure amplifies speculative claims while diminishing mechanistic constraints. The summary portrays AID as centrally positioned within a network of genome-wide interactions, implying that AID directs processes ranging from epigenetic remodeling to transcriptional reprogramming and metabolic adaptation. Such representations contradict established biochemistry demonstrating that AID’s mutator activity is tightly restricted, temporally constrained and mechanistically dependent on transcription-mediated ssDNA exposure. The summary model also conflates correlation with causation by depicting AID as the upstream driver of pathways that may simply co-occur during germinal center activation. For instance, DNA repair activation, metabolic stress and proliferative cues are all shown as downstream of AID, whereas experimental data demonstrate that these pathways are activated independently and influence the consequences of AID activity rather than being controlled by it. By visually elevating AID to the apex of regulatory hierarchies, the graphic obscures the dominant roles of BCL6, MYC, IRF4 and DNA damage sensors in shaping B cell outcomes. Finally, the graphical summary employs visually symmetric relationships that give speculative interactions equal weight to validated mechanisms. This creates a false sense of conceptual completeness, encouraging readers to view AID as an overarching regulator rather than as a tightly regulated mutator enzyme embedded within complex cellular systems. The figure therefore functions less as a summary of evidence and more as a visual argument for a model still lacking empirical foundation. 9. Extended Data (ED) Figure Critiques 9.1. Critical Analysis of ED Figure 1 ED Figure 1 appears intended to provide additional mechanistic depth to the review's portrayal of AID targeting, yet it suffers from conceptual overreach and insufficient attention to methodological limitations. The figure depicts a genomewide distribution of AID-associated DNA lesions, presented as if these patterns reflect a coordinated regulatory logic rather than a mixture of stochastic deamination events and repair-dependent variation. The heatmaps and genomic tracks suggest that AID targets broad sets of transcriptionally active genes, implying 25 a selective functional rationale. However, studies using high-resolution mapping approaches such as END-seq and R-loop profiling reveal that AID recruitment is highly dependent on local ssDNA exposure created by transcriptional pausing, Rloop persistence and enhancer-promoter looping rather than purposeful genomic selection. The figure does not clarify whether the displayed lesions result from direct AID catalytic activity or from secondary repair intermediates, nor does it distinguish between cell-cycle–dependent variation or chromatin-accessibility influences. The failure to differentiate these variables creates an impression of regulative specificity inconsistent with the biochemical constraints of the enzyme. Furthermore, the underlying data sources are not described in sufficient detail to assess reproducibility, and the selection of genomic loci highlighted in the figure appears curated to fit the authors' narrative rather than representing unbiased genomic sampling. As a result, the figure inflates the significance of off-target lesions and obscures the context-dependent nature of AID targeting. 9.2. Critical Analysis of ED Figure 2 ED Figure 2 attempts to validate the review's claims regarding the interaction between AID and transcriptional machinery by presenting co-localization analyses, immunoprecipitation data and chromatin-binding profiles. The figure illustrates AID enrichment at regions of stalled transcription, but the depiction assumes that AID is preferentially recruited to such sites through specific recognition of transcriptional pausing factors. This interpretation conflicts with biochemical evidence demonstrating that AID lacks known structural domains for recognizing pausing complexes and instead binds ssDNA opportunistically. The co-localization panels rely on imaging that does not possess the spatial resolution necessary to infer direct physical interactions. Moreover, the figure omits controls that would distinguish functional co-localization from stochastic overlap, such as comparisons with catalytically inactive AID mutants or with APOBEC family proteins exhibiting similar binding patterns. The immunoprecipitation data are similarly ambiguous, presented as evidence of AID association with transcriptional machinery but failing to account for indirect interactions mediated by nucleic acid scaffolding. Without nuclease-treated controls, the figure’s conclusions remain speculative. Additionally, the chromatinbinding profiles shown do not include negative controls for off-target binding, making it difficult to assess the specificity of the observed interactions. The figure thus overstates the mechanistic intimacy between AID and transcriptional pausing complexes and reinforces a model not firmly supported by empirical evidence. 32 clusters exhibit distinct transcriptional signatures and lower AID expression, while cells in metabolically restrictive niches show heightened AID activity and elevated DNA damage. These spatial gradients indicate that AID function is not an organizer of germinal center architecture, as the review implies, but rather a product of environmental constraints and microregional signaling. Spatial data also demonstrate that antigen availability, cell density, and stromal scaffold positioning contribute to the variability in AID activation. Ignoring these findings results in a conceptual model that disconnects AID from the physical structure of germinal centers, producing an abstraction that lacks biological granularity. The omission of spatial immunology is particularly problematic because it directly contradicts the review’s portrayal of AID as a master integrator of signals, when in reality AID is itself shaped by local environmental cues. 11.5. New Computational and Structural Biology Perspectives Finally, the review overlooks major methodological advances in computational modeling and structural biology that refine our understanding of AID’s targeting constraints and catalytic behavior. Molecular dynamics simulations have clarified the conformational instability of AID’s catalytic core, explaining its low basal activity and high dependence on transcription-associated ssDNA exposure. Predictive models of chromatin folding and enhancer-promoter interactions have shown that AID-accessible regions arise through passive exposure rather than through active recruitment. Machine learning approaches integrating mutational signatures across cancers have further revealed that AID’s off-target activity is constrained by a narrow set of sequence and structural determinants, contradicting the review’s claim of expansive genome-wide influence. Structural studies have also elucidated how protein instabilities, weak DNA-binding affinities and rapid nuclear export limit AID’s imprint on genomic architecture. The absence of these computational and structural insights from the review leads to a model that exaggerates AID’s mechanistic capacities and obscures the biochemical limitations that define its activity. 12. Integrative Evaluation of Mechanistic Claims 12.1. Strength of Mechanistic Evidence A central limitation of the reviewed article is the disparity between the strength of the mechanistic evidence available in the literature and the interpretive weight the authors assign to it. The review frequently elevates associative or correlative observations to mechanistic status without providing sufficient experimental grounding. For example, the authors cite co-localization data, transcriptional correlations and epigenetic signatures as if these observations directly demonstrate 33 that AID orchestrates chromatin remodeling or regulates transcriptional reprogramming. Yet mechanistic claims of this magnitude require biochemical validation, structural analyses and perturbation experiments, none of which are discussed in detail. The review’s broad narrative approach leads to an inflation of AID’s regulatory reach, positioning the enzyme as an upstream actor in processes where it is more accurately understood as a dependent or downstream participant. In reality, most mechanistic work characterizes AID as a highly restricted deaminase whose enzymatic activity is governed by ssDNA availability, transcriptional architecture and nuclear export constraints. The review’s unwillingness to calibrate its claims to the strength of the underlying evidence creates a conceptual mismatch that undermines its scientific rigor. By anonymizing mechanistic uncertainty and blending speculative models with established pathways, the review sacrifices precision in favor of narrative cohesion. 12.2. Proven vs. Speculative Claims in the Review A recurring theme in the review is the failure to distinguish clearly between experimentally validated mechanisms and speculative extensions of existing models. Proven aspects of AID biology—such as its requirement for transcriptioncoupled ssDNA exposure, the role of uracil processing in generating somatic hypermutation and class-switch recombination and the dependence of off-target activity on chromatin accessibility—are presented alongside hypothetical roles in epigenetic regulation, metabolic adaptation and genome-wide architectural modulation. This blending of established findings with conjecture creates interpretive ambiguity, as readers may infer that all proposed functions are supported by comparable levels of evidence. In several instances, speculative claims contradict recent biochemical and genomic studies. For example, the review reiterates models of AID-mediated demethylation that have been mechanistically refuted, reviving outdated hypotheses in a way that obscures the current consensus. The suggestion that AID shapes enhancer–promoter communication or contributes to 3D genome folding is similarly unsubstantiated. Even when speculative claims are presented as possibilities rather than certainties, the absence of caveats or mechanistic constraints encourages readers to view them as plausible extensions rather than as hypotheses requiring rigorous validation. This conflation of the speculative and the demonstrated reduces the review’s contribution to scientific clarity. 12.3. Contradictions with Recent Structural Studies Recent structural and biophysical analyses offer a more restrictive and nuanced view of AID function than the review acknowledges, resulting in several conceptual contradictions. Structural studies demonstrate that AID possesses limited catalytic 34 efficiency, low DNA-binding affinity and substantial conformational instability, all of which constrain its activity to contexts where ssDNA is exposed long enough for deamination to occur. These biochemical limitations directly contradict the review’s portrayal of AID as a versatile, genome-wide regulatory agent. Molecular modeling also reveals that AID lacks the structural motifs required for direct interactions with chromatin remodelers or transcriptional complexes, undermining claims that AID actively shapes epigenetic landscapes or transcriptional dynamics. Additionally, studies using single-molecule imaging and mutational profiling have shown that AID deamination is inherently probabilistic rather than directed, challenging the review’s implication of purposeful targeting. The review also disregards the importance of rapid nuclear export in limiting AID’s genomic exposure; structural analyses demonstrate that destabilizing features in AID’s architecture necessitate tight post-translational regulation to prevent excessive mutagenesis. These structural constraints render several claims in the review physically implausible, and their omission represents a substantive conceptual oversight. By not integrating structural data, the review builds mechanistic narratives incompatible with the enzyme’s known biochemical properties. 12.4. Synthesis of Neglected Alternative Hypotheses Finally, the review overlooks alternative mechanistic hypotheses that could challenge or refine its proposed model of AID as a global regulatory integrator. One such hypothesis posits that many phenomena attributed to AID are emergent rather than purposeful: they arise from interactions among transcriptional activity, replication stress, chromatin accessibility and DNA repair capacity rather than from AID exerting direct regulatory control. This emergent framework aligns closely with multi-omics and cancer genomic data showing that AID’s off-target effects correlate strongly with structural genome features rather than with specific functional pathways. Another alternative explains AID-associated epigenetic patterns as indirect outcomes of localized DNA repair, transcriptional disruption or chromatin loosening, rather than as deliberate epigenetic editing. Additionally, the stochastic model of germinal center evolution views AID-induced mutations as raw material shaped almost entirely by selection pressures and environmental cues, without requiring AID to coordinate differentiation or selection outcomes. These alternative models are better aligned with empirical evidence and address inconsistencies in the review’s claims, yet they receive no substantive discussion. The omission of competing hypotheses narrows the conceptual landscape and limits the review’s interpretive robustness. A comprehensive synthesis would evaluate the relative explanatory power of multiple mechanistic frameworks rather than privileging a single speculative model. 35 13. Implications for Immunopathology and Cancer 13.1. AID-Driven Mutagenesis in B Cell Lymphoma AID’s essential role in antibody diversification inevitably links it to the mutational processes that drive B cell malignancies. However, the review offers an incomplete and at times overly benign depiction of AID’s oncogenic potential. In B cell lymphomas, including diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma and Burkitt lymphoma, mutational landscapes reveal extensive offtarget AID activity. These mutational signatures encompass kataegis, clustered hypermutation, aberrant somatic hypermutation and translocations that juxtapose oncogenes with strong immunoglobulin enhancers. The review acknowledges AID’s involvement in lymphoma genesis but does not engage with new genomic studies demonstrating that AID contributes to mutational burdens at thousands of off-locus regions, many of which encode tumor suppressors or proliferation-associated genes. These datasets contradict the review’s suggestion that AID-induced damage is broadly regulated or functionally purposeful. Instead, they point to AID as a major driver of genomic instability when regulatory systems fail or when AID expression becomes decoupled from germinal center homeostasis. Additionally, the review does not address evidence that germinal center B cells accumulate DNA lesions more rapidly than repair systems can manage, creating a reservoir of potentially oncogenic mutations that persist through clonal selection. Without integrating these perspectives, the review presents an incomplete and sanitized view of how AID’s beneficial roles coexist with potent oncogenic risks. 13.2. Autoimmune Disorders and Inappropriate AID Expression Autoimmune diseases frequently involve aberrant AID expression, yet the review gives only superficial attention to these pathologies. In conditions such as systemic lupus erythematosus, rheumatoid arthritis and Sjögren’s syndrome, AID activity is often elevated not only in germinal centers but also in extrafollicular regions where tolerance mechanisms are weakened. This aberrant expression contributes to the generation of high-affinity autoreactive antibodies, class-switch recombination outside regulated microenvironments and the development of pathogenic plasma cells. The review neglects these observations and fails to consider how mislocalized or dysregulated AID expression directly destabilizes immune tolerance. Studies have shown that inflammatory cytokines such as IFN-α and IL-21 can induce ectopic AID expression in autoreactive B cell populations, leading to expansion of selfreactive clones and increased somatic hypermutation within autoreactive BCR repertoires. Furthermore, AID-induced DNA damage in non-lymphoid cells, 36 particularly epithelial cells, has been implicated in autoimmune tissue degeneration. By omitting these mechanistic links, the review not only overlooks major pathological consequences of AID dysregulation but also misses an opportunity to contextualize AID within the broader network of immune tolerance, chronic inflammation and breakage of self-recognition. This omission diminishes the review’s ability to function as a comprehensive synthesis of AID’s physiological and pathological reach. 13.3. AID’s Role in Viral Immunopathology AID can be induced during chronic viral infections, yet the review does not explore how this relationship contributes to immunopathology or cancer risk. Viruses such as hepatitis B virus, hepatitis C virus, Epstein–Barr virus and human papillomavirus can stimulate AID expression either directly through viral protein interactions or indirectly through inflammatory cytokines. In hepatocytes, aberrant AID expression contributes to mutational signatures characteristic of hepatocellular carcinoma, including clusters of C→T transitions associated with APOBEC-family mutagenesis. Similarly, EBV infection modulates AID expression in B cells, contributing to lymphomagenesis through increased somatic hypermutation of oncogenes and accumulation of DSBs that can facilitate translocations. The review does not address these viral contexts, nor does it discuss how AID-induced mutations in infected cells interact with viral oncogenes or chronic inflammatory microenvironments. Additionally, chronic viral infections often distort germinal center architecture, shifting AID activity toward extrafollicular activation pathways where regulatory control is weaker. This spatial redistribution increases the likelihood of off-target deamination events and genomic instability. By ignoring these connections, the review misses critical interactions between viral pathogenesis, host response and AID dysregulation, thereby failing to capture the full spectrum of AID-mediated immunopathology. 13.4. Failure of the Review to Contextualize Risk Factors Perhaps the most problematic omission in the review is its failure to contextualize the risk factors that shape AID’s pathological consequences. AID activity cannot be meaningfully interpreted in isolation from environmental and cellular conditions that determine whether its mutagenic potential remains beneficial or becomes damaging. Factors such as chronic inflammation, sustained antigen exposure, environmental mutagens, age-related DNA repair decline, dysregulated Tfh signaling and germinal center hyperplasia all contribute to environments in which AID-driven damage accumulates beyond physiological thresholds. Yet the review approaches AID as though its functions exist independently from these modifying forces. This oversight leads to an overly deterministic model wherein AID’s mutagenic activity is 37 portrayed as integrative or adaptive rather than contingent on contextual constraints. The failure to address risk factors also allows the review to understate the fragility of the balance between effective antibody diversification and detrimental genomic instability. Moreover, emerging evidence indicates that metabolic stress, hypoxia and replication burden in germinal centers increase the likelihood of AID off-target activity, yet these contexts are not incorporated into the review’s interpretive framework. Without integrating risk-modifying conditions, the review misrepresents AID’s dual role as both an essential immunological tool and a potent threat to genomic integrity. 14. Translational and Therapeutic Dimensions 14.1. AID Inhibition as a Therapeutic Strategy Therapeutically targeting AID has long been proposed as a strategy to mitigate its mutagenic consequences in cancer and autoimmunity, yet the review barely engages with this translational frontier. AID inhibition presents both conceptual promise and significant biochemical challenges. Because AID’s catalytic pocket resembles those of other APOBEC-family deaminases, designing selective inhibitors requires exceptional specificity to avoid off-target suppression of innate antiviral enzymes. Recent structural studies have identified transient conformational states in AID that could serve as selective inhibitor binding sites, but these insights are absent from the review. Moreover, AID’s low nuclear abundance and dynamic trafficking pose additional challenges for pharmacologic targeting, as inhibiting cytoplasmic pools may not meaningfully reduce genomic mutagenesis. Nonetheless, chemical scaffolds capable of chelating AID’s active-site zinc or stabilizing non-productive conformations have emerged as promising leads in preclinical models. The review’s omission of these developments creates a conceptual vacuum, suggesting that therapeutic modulation of AID remains entirely speculative when in fact the field has begun to identify actionable strategies. Furthermore, targeted inhibition could be beneficial in contexts such as germinal center hyperplasia, chronic viral infection or autoimmune disease, where AID overexpression contributes to pathology. By failing to integrate these therapeutic insights, the review neglects one of the most clinically relevant aspects of contemporary AID research. 14.2. Missing Discussion of Druggability A major limitation of the review is its lack of discussion on AID’s druggability, particularly in regard to small molecules, biologics and targeted degradation approaches. The physical properties of AID—its instability, low intrinsic DNAbinding affinity and rapid nuclear export—make it appear resistant to drug development, yet these same properties offer unique therapeutic entry points. 38 Protein destabilization domains within AID could be exploited through targeted protein degradation technologies such as PROTACs or molecular glues. Recent work has shown that modifying nuclear import signals or interfering with CRM1mediated export can modulate AID’s nuclear residency, suggesting that therapeutic modulation of trafficking rather than catalytic activity could be a viable strategy. Additionally, inhibiting co-factors required for AID processivity, such as Spt5 or RPA, may selectively reduce mutagenic capacity without abolishing beneficial antibody diversification during acute immune responses. None of these possibilities are acknowledged in the review. This omission is particularly striking given that druggability has become a central theme in modern immunology research, with the translation of biochemical insights into therapeutic interventions now a core expectation. By excluding druggability considerations, the review fails to connect mechanistic understanding with potential clinical applications. 14.3. Failure to Integrate Structural Drug Design Structural drug design has advanced rapidly, offering unprecedented opportunities to rationally inhibit or modulate AID, yet the review does not mention any of these developments. High-resolution NMR and cryo-EM studies have revealed transiently exposed hydrophobic pockets and flexible loops near AID’s active site that could be exploited by small molecules to stabilize non-functional conformations. Computational screening methods have begun identifying candidate compounds that mimic cytidine substrates but trap AID in catalytically incompetent states. Machine learning algorithms trained on APOBEC-family structures have predicted drug-binding surfaces unique to AID, which provide a roadmap for selective inhibitor development. The review’s failure to discuss these advances neglects the translational momentum building in the field. Additionally, structural insights have implications beyond pharmacologic inhibition; understanding how AID interacts with nucleic acids and protein partners informs strategies for gene therapy, targeted mutagenesis control and the design of engineered deaminases with reduced offtarget effects. Without integrating structural drug design perspectives, the review reinforces an outdated perception of AID as a mechanistically opaque and therapeutically inaccessible enzyme, rather than recognizing it as an emerging target for precision intervention. 14.4. Implications for Vaccine Design Perhaps the most surprising omission in the review is its failure to connect AID biology to vaccine design, despite AID’s central role in shaping affinity maturation, generating broadly neutralizing antibodies and supporting durable humoral immunity. Manipulating AID activity has the potential to enhance vaccine efficacy by influencing the breadth and durability of antibody responses. For example, 39 transiently increased AID expression during vaccination could expand the mutational landscape available for affinity maturation, potentially accelerating the emergence of high-affinity or broadly neutralizing antibodies. Conversely, excessive AID activity during vaccination carries risks of genomic instability in activated B cells, underscoring the need for calibrated modulation rather than global enhancement. Studies in HIV, influenza and coronavirus vaccines have demonstrated that germinal center longevity and iterative cycles of somatic hypermutation are critical for producing protective antibody responses. Modulating Tfh–B cell interactions, metabolic states or cytokine cues that indirectly shape AID expression could improve vaccine-induced immunity. The review does not acknowledge these translational implications or the extensive literature linking AID dynamics to vaccination outcomes. Moreover, recent mRNA vaccine platforms generate robust germinal center responses, making AID-related mutational processes more relevant than ever to rational vaccine design. By excluding these considerations, the review overlooks a vital bridge between fundamental AID biology and real-world immunological interventions. 15. Future Directions and Conceptual Corrections 15.1. Rebuilding a Mechanistic Model of AID A more coherent and experimentally grounded model of AID must begin with mechanistic humility, acknowledging the biochemical constraints and structural limitations that define the enzyme’s natural range of activity. Rather than positioning AID as a genome-wide regulatory integrator, future frameworks should treat AID as a highly regulated mutator whose consequences are shaped primarily by the interplay of transcriptional architecture, DNA repair dynamics and microenvironmental context. A revised model would emphasize that AID operates most effectively within narrow windows of nuclear exposure, during specific cellcycle phases and in chromatin regions undergoing transcription-generated ssDNA formation. This tighter framing aligns with structural studies showing low intrinsic catalytic efficiency and high dependency on co-factors such as RPA and Spt5 for productive engagement with DNA. Rebuilding the mechanistic model also requires abandoning unsupported assumptions about AID’s involvement in direct epigenetic modulation or 3D genome organization. Instead, the model should incorporate the emerging view that many downstream effects attributed to AID are emergent properties of DNA damage and repair-mediated chromatin remodeling rather than intentional regulatory processes. A refined mechanistic framework will allow researchers to disentangle causality from correlation and better predict where and when AID exerts physiologically relevant influence. 40 15.2. Required Datasets and Experimental Approaches Advancing beyond speculative models will require high-resolution, multi-modal datasets capable of resolving AID action with temporal, spatial and biochemical precision. Single-cell multi-omics—integrating transcriptional, epigenomic, proteomic and DNA damage profiling—should be employed to map heterogeneity in AID expression, catalytic activity and repair pathway usage across germinal center states. Temporal resolution is especially critical: methods such as time-resolved CUT&RUN, metabolic labeling of nascent mutations, and synchronized cell-cycle studies can determine the precise order of molecular events following AID expression. Spatial transcriptomics and imaging mass cytometry can elucidate how microenvironmental variation in germinal centers influences AID activity. Furthermore, structural biology must continue identifying transient conformational states and catalytic constraints that inform both mechanistic understanding and drug design. CRISPR interference screens can reveal regulatory networks that modulate AID levels, trafficking, degradation and co-factor engagement, allowing systematic identification of restraining mechanisms. Importantly, perturbation experiments using catalytically inactive or trafficking-deficient AID mutants will be necessary to differentiate catalytic from non-catalytic functions. Together, these approaches can replace the narrative-driven models criticized in the review with experimentally grounded mechanistic clarity. 15.3. Proposed Conceptual Reframing A conceptual reframing of AID’s role in adaptive immunity should emphasize three core principles: constraint, contingency and consequence. Constraint acknowledges that AID’s biochemical and structural limitations restrict it to narrow genomic contexts defined by transcriptional and chromatin architecture. This principle contradicts attempts to portray AID as a broad, intentional regulator of genome function. Contingency highlights that AID’s effects depend almost entirely on environmental and cellular conditions, including microanatomical positioning within germinal centers, cytokine signals, replication stress and DNA repair capacity. These conditions determine whether AID-induced mutations are beneficial, neutral or catastrophic, and they underscore that AID’s biological influence is far from uniform or deterministic. Consequence centers on the dual nature of AID activity: while essential for generating antibody diversity, AID simultaneously produces genomic instability that contributes to autoimmunity, cancer and immunopathology. Recognizing this duality demands a framework that integrates evolutionary trade-offs rather than presuming coherent regulatory intent. This reframed model rejects teleological interpretations and instead situates AID within a probabilistic, selection-driven landscape where its mutagenic output is 41 shaped by cellular constraints and filtered by immune pressures. By adopting a conceptual foundation grounded in molecular realism rather than speculative integration, future research can more accurately delineate AID’s role in immunity and disease. 16. Conclusion 16.1. Synthesis of Major Criticisms The review by Carvalho, Fagarasan and Muramatsu aspires to elevate AID from a specialized mutator enzyme to a unifying regulator of genomic architecture, epigenetic remodeling and adaptive immune coordination. However, this commentary has demonstrated that the review’s central arguments rest on conceptual inflation, selective citation and insufficient engagement with mechanistic constraints. Across molecular, cellular and systems-level dimensions, the review overstates AID’s scope of influence while underrepresenting the biochemical, structural and regulatory limitations that define its activity. The figures and extended datasets accompanying the review compound these issues by visually reinforcing speculative narratives without providing the experimental rigor necessary to substantiate such claims. Critical dimensions of AID biology— heterogeneity within germinal centers, stochasticity of target-site exposure, limitations imposed by nuclear trafficking, and the primacy of environmental cues— are either marginalized or ignored entirely. Consequently, the proposed integrative model of AID lacks coherence, mechanistic plausibility and compatibility with contemporary multi-omic and structural findings. 16.2. Broader Relevance for Immunology AID is undeniably central to adaptive immunity, enabling the somatic evolution of antibody repertoires that protect vertebrates from an enormous diversity of pathogens. However, the field has increasingly recognized that AID’s mutagenic power must be understood through a lens of constraint rather than expansiveness. The enzyme’s activity represents a carefully managed biological risk—essential for generating immunity yet hazardous when dysregulated. Mischaracterizing AID as a deliberate genome sculptor shifts focus away from the complex interplay of DNA damage responses, selection pressures, metabolic conditions and microanatomical cues that collectively shape antibody maturation. Such misinterpretations have implications not only for mechanistic immunology but also for fields ranging from autoimmunity to cancer genomics. A clearer and more grounded understanding of AID is required to inform translational efforts, whether aimed at improving vaccine design, mitigating mutational burdens in lymphoid malignancies or designing targeted interventions to modulate AID activity in chronic inflammatory disease.